Syn th esis of Er yth r om ycin Der iva tives via th e Olefin
Cr oss-Meta th esis Rea ction
†
‡
Margaret C. Hsu,* Adam J . J unia, Anthony R. Haight, and Weijiang Zhang
Process Chemistry Research and Development, Global Pharmaceutical R&D, Abbott Laboratories,
1
401 Sheridan Road, North Chicago, Illinois 60064
Received February 13, 2004
Olefin cross metathesis (CM) was applied to the synthesis of 6-O-substituted erythromycin
derivatives. The reactions were catalyzed by transition metal alkylidene complexes, particularly
bis(tricyclohexylphosphine)benzylidine ruthenium (IV) dichloride (Grubbs’ first-generation catalyst).
This approach allowed for the elaboration of the 6-O-allyl group of highly functionalized macrolides
at various stages of the synthetic sequence, affording 6-O-3-aryl-propenyl products with excellent
E-selectivity. Little or no self-dimerization of the reacting components was found in the crude
mixtures. Preliminary kinetic data accounts for the observed cross-selectivity based on substrate
reactivity and steric factors.
In tr od u ction
ABT-773 (1) is a semi-synthetic ketolide anti-infective
candidate previously selected for clinical development at
1
Abbott Laboratories. Beginning with erythromycin A (2),
a sequence of chemical reactions are applied to effect the
following overall transformations: (a) elaboration at the
6
-hydroxyl group, (b) 11,12-cyclic carbamate formation
from the corresponding diol, and (c) cladinose hydrolysis
2
and oxidation at the 3-position. Of these three transfor-
mations, the construction of the 6-O-3-(3′-quinolyl)-
propenyl side chain poses the greatest opportunity for
exploring various synthetic approaches. Herein, we report
the application of olefin cross metathesis (CM) to eryth-
romycin derivatives.
The application of olefin metathesis in organic synthe-
3
ses has gained popularity in recent years due, in large
part, to the commercial availability of well-defined cata-
†
Current address: Department of Chemistry, 907 Washington
Street, Northwestern University, Evanston, IL 60202.
‡
Current address: Theravance Inc., 901 Gateway Blvd., South San
Francisco, CA 94080.
(1) (a) Or, Y. S.; Ma, Z.; Clark, R. F.; Chu, D. T.; Plattner, J . J .;
Griesgraber, G. U.S. Patent 5,866,549, 1999. (b) Or, Y. S.; Ma, Z.; Clark,
R. F.; Chu, D. T.; Plattner, J . J .; Griesgraber, G. U.S. Patent 6,028,-
1
81, 2000. (c) Or, Y. S.; Ma, Z.; Clark, R. F.; Chu, D. T.; Plattner, J . J .;
Griesgraber, G. U.S. Patent 6,075,133, 2000.
2) Stoner, E. J .; Peterson, M. J .; Ku, Y.; Cink, R. D.; Cooper, A. J .;
(
Deshpande, M. N.; Grieme, T.; Haight, A. R.; Hill, D. R.; Hsu, M. C.;
King, S. A.; Leanna, M. R.; Lee, E. C.; McLaughlin, M. A.; Morton, H.
E.; Napier, J . J .; Plata, D. J .; Raje, P. S.; Rasmussen, M.; Riley, D.;
Tien, J . J .; Wittenberger, S. J . U.S. Patent 6,437,106 B1, 2002.
(3) For recent reviews on olefin metathesis, see: (a) Handbook of
Metathesis; Grubbs, R. H., Ed.; Wiley-VCH: Weinheim, 2003. (b)
Trnka, T. M.; Grubbs, R. H. Acc. Chem. Res. 2001, 34, 18-29. (c)
Furstner, A. Angew. Chem., Int. Ed. 2000, 39, 3012-3043. (d) Roy,
R.; Das, S. K. Chem. Commun. 2000, 519-529. (e) Philips, A. J .; Abell,
A. D. Aldrichimica Acta 1999, 32, 75-90. (f) Armstrong, S. K. J . Chem.
Soc., Perkin Trans. 1 1998, 371-388. (g) Grubbs, R. H.; Chang, S.
Tetrahedron 1998, 54, 4413-4450. (h) Ivin, K. J . J . Mol. Catal. A:
Chem. 1998, 133, 1-16. (i) Randall, M. L.; Snapper, M. L. J . Mol. Catal.
A: Chem. 1998, 133, 29-40. (j) Schuster, M.; Blechert, S. Angew.
Chem., Int. Ed. Engl. 1997, 36, 2036-2056.
lysts such as the Grubbs’ (3)4 and the Schrock’s (4)5
catalysts. A cursory overview of the chemical literature
reveals that C-C double bond formation via olefin
(4) Schwab, P.; Grubbs, R. H.; Ziller, J . W. J . Am. Chem. Soc. 1996,
118, 100-110.
1
0.1021/jo049737n CCC: $27.50 © 2004 American Chemical Society
Published on Web 05/01/2004
J . Org. Chem. 2004, 69, 3907-3911
3907